Deep Molecular Remission Predicts Better Clinical Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene Autoleucel (obe-cel)
Elias Jabbour(The University of Texas MD Anderson Cancer Center), Claire Roddie(Cancer Institute (WIA)), Mehrdad Abedi(UC Davis Comprehensive Cancer Center), Bijal Shah(Boston College), Pierre Lao‐Sirieix(Autolus (United Kingdom)), Paul Shaughnessy(CHRISTUS Transplant Institute), Aaron C. Logan(University of California, San Francisco), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Yiyun Zhang, Jae H. Park(Memorial Sloan Kettering Cancer Center), Michael Bishop(Peter MacCallum Cancer Centre), Karamjeet Sandhu, Wolfram Brugger
Cited by 2
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations
|Biology of Blood and Marrow Transplantation|2013|402